Search

everythinglearnresearchcommunity

for

Search:↓

Kintor Pharma has started a Phase II trial in China for GT20029, a potential new treatment for hair loss. Participants are discussing the significance, potential release dates, and comparing it to other treatments and technologies like stem cell hair transplants and SAMIRNA.

The effectiveness of microneedling as a hair loss treatment, with evidence from studies and anecdotal accounts from other users. It is suggested that combining microneedling with minoxidil or finasteride may be more effective than using microneedling alone, although some people have had success using only microneedling.

People discussed using peppermint, lavender, rosemary, and pumpkin seed oils for hair regrowth or thickening. They shared personal experiences and recommendations on using these oils alone or in combination.

A Phase II clinical trial for TDM-105795 has started recruiting in the US, and it might be a promising treatment for hair loss. Many hair loss drugs, including this one, originate from China.

Treatments for hair loss, specifically the use of minoxidil, finasteride and RU58841. Replies to this post suggest that users should share relevant information publicly rather than through direct messages.

Rosemary Oil may inhibit the activity of 5α-Reductase, potentially promoting hair growth. Specific treatments discussed include Minoxidil, Finasteride, and RU58841.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

Botox injections on the scalp may help with hair loss, as one small study showed improvement in 8 out of 10 subjects. Treatments mentioned include Minoxidil, finasteride, and RU58841.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

The conversation discusses potential advancements in two hair loss drugs, KX-826 and GT20029, and the interest in whether transitioning from oral finasteride to these drugs would maintain hair growth. One reply expresses skepticism about the compounds' representation.

Kintor Pharma completed enrolling subjects for a Phase III trial of KX-826 for male hair loss treatment. The trial includes a 24-week treatment period and a 4-week safety follow-up, with results expected in about 6-7 months.

The potential availability of a new hair loss treatment called HMI-115, which has shown promising results in experiments on monkeys but is not yet available to the public. Replies cautioned against using unproven substances from shady labs.

Treatments for hair loss, such as Minoxidil, Finasteride and RU58841, as well as using serrapeptase to break up scar tissue in the scalp.

The impact of creatine on DHT levels, and whether it could cause accelerated male pattern baldness (MPB). The user taking a 5 alpha reductase inhibitor found that their DHT levels actually reduced despite taking creatine for nine weeks. Replies suggested looking into testosterone levels as well and debating the safety of creatine use in relation to MPB.

Researching and developing an effective local antagonist to block the androgen receptors for hair loss, as opposed to using DHT synthesis inhibitors that lower serum DHT levels. Several treatments such as CosmeRNA and Pyrilutamide are currently in development or undergoing trials.

Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.

A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.

HMI-115, a potential treatment for hair loss that can reverse miniaturization and make individual hairs thicker, as evidenced by data from macaques given the treatment and one subject in the phase I trial.

Hair loss, genetics and possible treatments such as minoxidil, dermarolling and finasteride.

Hair loss linked to DHT and prolactin levels. Hmi-115 cure discussed, along with Minoxidil, Finasteride, and RU58841 treatments.

A user shared their experience with Finasteride for hair loss, noting a significant reduction in DHT levels and a complete loss of libido without other side effects. Another user agreed, discussing the negative impact on sexual drive and criticizing the community's attitude towards discussing side effects.

The user experienced significant hair shedding in the second week of using pyrilutamide, more so than with finasteride and minoxidil, and reported a headache after the first application. They believe the treatment may be working but acknowledge it's too early to confirm results.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

AnagenInc is ready to produce a hair loss treatment called GT20029 if there is enough demand. People are discussing combining it with other treatments like finasteride and minoxidil, and some are concerned about the legitimacy and safety of gray market products.

The conversation discusses using Tretinoin for treating androgenic alopecia. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.

Researching the effects of scalp trauma on hair growth, with some users suggesting experimenting with a soldering iron or derma pen, and others bringing up studies that suggest this may be an effective treatment.

The conversation warns about taking information on pyrilutamide with skepticism, suggesting that many may not have the genuine product. It advises to wait for FDA approval for reliable information.

The conversation is about the anticipated release timeline for a hair loss treatment called GT20029. It may be available on the gray market in 1-2 years and officially in 3-4 years after completing clinical trials.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115 release timeline is uncertain, with possible grey market availability in 2024-2025.